Drug Profile
Glycopyrrolate inhalation - Chiesi
Alternative Names: CHF-5259; Extrafine glycopyrronium bromide pMDILatest Information Update: 10 Feb 2023
Price :
$50
*
At a glance
- Originator Chiesi
- Class Antiasthmatics; Antispasmodics; Antiulcers; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules
- Mechanism of Action Muscarinic M3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 04 Sep 2022 Pharmacodynamics data from preclinical trial in Asthma presented at the 32nd Annual Congress of the European Respiratory Society (ERS-2022)
- 17 May 2019 Efficacy and safety data from the phase II GLIMMER trial in Chronic obstructive pulmonary disease presented at the 115th International Conference of the American Thoracic Society (ATS-2019)
- 06 Jun 2018 Chiesi completes a phase II trial in Chronic obstructive pulmonary disease in USA (Inhalation) (NCT03084796)